Venus Medtech Hangzhou 주식 주식분석 | 주식가격 | 뉴스 | 2500.HK | CNE100003PJ8 | | 2025년 8월

날짜	Venus Medtech Hangzhou 주식 가격
	4.32 undefined
	4.24 undefined
	4.24 undefined
	4.51 undefined
	4.58 undefined
	4.12 undefined
	3.81 undefined
	3.89 undefined
	4.02 undefined
	4.06 undefined
	3.62 undefined
	3.41 undefined
	3.71 undefined
	3.77 undefined
	3.38 undefined
	3.15 undefined
	3.13 undefined
	3.24 undefined
	2.73 undefined
	2.53 undefined
	2.54 undefined

날짜	Venus Medtech Hangzhou 매출	Venus Medtech Hangzhou EBIT	Venus Medtech Hangzhou 이익
2029e	4.51 조. undefined	1.06 조. undefined	0 undefined
2028e	3.76 조. undefined	896.31 백만 undefined	0 undefined
2027e	2.92 조. undefined	678.65 백만 undefined	0 undefined
2026e	807.59 백만 undefined	-119.43 백만 undefined	-111.66 백만 undefined
2025e	738.47 백만 undefined	-264.73 백만 undefined	-290.33 백만 undefined
2024	470.83 백만 undefined	-734.76 백만 undefined	-714.31 백만 undefined
2023	491.37 백만 undefined	-718.25 백만 undefined	-703.75 백만 undefined
2022	406.46 백만 undefined	-1.19 조. undefined	-1.06 조. undefined
2021	415.86 백만 undefined	-420.25 백만 undefined	-373.64 백만 undefined
2020	276.05 백만 undefined	-262.4 백만 undefined	-181.99 백만 undefined
2019	233.27 백만 undefined	-363.61 백만 undefined	-380.72 백만 undefined
2018	115.35 백만 undefined	-305.8 백만 undefined	-300.42 백만 undefined
2017	18.16 백만 undefined	-155.96 백만 undefined	-156.53 백만 undefined

2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e
0.02	0.12	0.23	0.28	0.42	0.41	0.49	0.47	0.74	0.81	2.92	3.76	4.51
-	538.89	102.61	18.45	50.36	-2.17	20.94	-4.28	57.02	9.35	261.71	28.85	19.81
83.33	85.22	83.26	82.25	78.07	77.09	79.23	78.09	49.73	45.48	12.57	9.76	8.14
15	98	194	227	324	313	389	367	0	0	0	0	0
-156	-300	-380	-181	-373	-1,057	-703	-714	-290	-111	0	0	0
-	92.31	26.67	-52.37	106.08	183.38	-33.49	1.56	-59.38	-61.72	-	-	-
314.15	314.15	311.04	409.27	438.58	437.9	437.9	437.9	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023	2024

0.07	0.16	2.41	2.71	2.96	1.88	0.78	0.31
17.87	80.65	162.2	231.03	302.1	303.39	290.61	198.57
0.28	0.09	20.42	44.55	53.8	80.75	164.44	163.61
9.42	16.69	24.79	59.9	90.52	104.4	112.94	98.06
22.03	28.3	283.79	316.78	38	101	258.44	36.54
0.12	0.29	2.9	3.36	3.44	2.47	1.61	0.8
18.75	46.73	61.12	109.61	261.55	472.02	700.29	523.9
28.1	29.48	29.74	108.99	569.53	477.08	510	414.59
0	0	0	0	53.8	80.75	0	0
23.73	191.12	185.15	233	304.74	611.17	551.02	439.72
0	0.47	0.48	0.49	0.52	1.24	1.02	1.04
1.76	4.55	8.73	18.87	14.3	15.06	19.98	29.44
0.07	0.74	0.76	0.96	1.72	2.89	2.81	2.45
0.19	1.03	3.67	4.32	5.16	5.36	4.41	3.25

34.8	300	404.47	422.97	441.01	441.01	441.01	441.01
0	0.2	2.92	3.94	5.11	5.11	5.11	5.11
38.71	-45.52	-305.54	-478.53	-852.16	-1,907.58	-2,611.27	-3,325.58
0.89	8.14	15.33	-37.19	-54.72	63.39	79.66	100.42
-2.11	-0.72	-0.47	-30.81	-28.22	-28.69	-28.48	-44.49
0.07	0.46	3.04	3.82	4.62	3.68	2.99	2.28
2.94	0.98	1.45	5.3	8.75	9.13	33.86	30.23
11.92	42.94	29.89	37.5	41.71	44.91	35.12	52.41
48.95	366.25	408.13	351.64	135.45	192.01	241.49	223
30	80	120	0	4.9	0	136.83	17.52
2.16	5.96	8.99	11.09	17.73	246.06	357.87	38.59
95.97	496.13	568.46	405.52	208.53	492.1	805.17	361.75
3.92	15.36	17.31	21.67	48.15	653.58	331.49	312.98
0	38.73	37.29	32.94	53.45	17.41	17.78	0
12.92	13.8	0	1.06	167.48	488.43	339.94	363.94
0.02	0.07	0.05	0.06	0.27	1.16	0.69	0.68
0.11	0.56	0.62	0.46	0.48	1.65	1.49	1.04
0.19	1.03	3.66	4.28	5.1	5.33	4.49	3.32

2017	2018	2019	2020	2021	2022
-157	-299	-381	-185	-377	-1,156
6	10	28	37	51	112
0	0	0	0	0	0
-5	-101	-78	-112	-126	-124
74	240	127	23	-4	439
1	3	8	2	1	43
0	0	5	5	8	3
-82	-151	-303	-237	-456	-729
-19	-26	-24	-124	-145	-178
-46	-194	-30	-297	-653	-1,072
-27	-167	-6	-173	-507	-893
0	0	0	0	0	0
28	17	32	144	227	701
0	0	2.68	1.03	1.12	0
0.17	0.45	2.58	0.93	1.39	0.64
144	435	-133	-251	45	-66
0	0	0	0	0	0
0.05	0.11	2.25	0.29	0.25	-1.08
-101.73	-178	-327.82	-361.05	-602.08	-908.23
0	0	0	0	0	0

Venus Medtech Hangzhou 브루토마진	Venus Medtech Hangzhou 이익 마진	Venus Medtech Hangzhou EBIT-마진	Venus Medtech Hangzhou 이익 마진
2029e	78.11 %	23.57 %	0 %
2028e	78.11 %	23.83 %	0 %
2027e	78.11 %	23.25 %	0 %
2026e	78.11 %	-14.79 %	-13.83 %
2025e	78.11 %	-35.85 %	-39.31 %
2024	78.11 %	-156.06 %	-151.71 %
2023	79.21 %	-146.17 %	-143.22 %
2022	77.25 %	-293.31 %	-260.22 %
2021	77.99 %	-101.05 %	-89.85 %
2020	82.33 %	-95.05 %	-65.93 %
2019	83.45 %	-155.88 %	-163.21 %
2018	85.81 %	-265.11 %	-260.45 %
2017	83.06 %	-858.62 %	-861.77 %

날짜	Venus Medtech Hangzhou 주당 매출	Venus Medtech Hangzhou EBIT 당 주식	Venus Medtech Hangzhou 주당 이익
2029e	10.29 undefined	0 undefined	0 undefined
2028e	8.59 undefined	0 undefined	0 undefined
2027e	6.67 undefined	0 undefined	0 undefined
2026e	1.84 undefined	0 undefined	-0.26 undefined
2025e	1.69 undefined	0 undefined	-0.66 undefined
2024	1.08 undefined	-1.68 undefined	-1.63 undefined
2023	1.12 undefined	-1.64 undefined	-1.61 undefined
2022	0.93 undefined	-2.72 undefined	-2.42 undefined
2021	0.95 undefined	-0.96 undefined	-0.85 undefined
2020	0.67 undefined	-0.64 undefined	-0.44 undefined
2019	0.75 undefined	-1.17 undefined	-1.22 undefined
2018	0.37 undefined	-0.97 undefined	-0.96 undefined
2017	0.06 undefined	-0.5 undefined	-0.5 undefined

EPS-예상치	EPS-실제	보고 분기
-0.42	-0.47 (-12.39 %)	2024 Q2
-0.6	-0.85 (-41.24 %)	2023 Q4
-0.68	-0.8 (-17.06 %)	2023 Q2
-0.33	1.96 (700.49 %)	2022 Q4
-0.13	-0.46 (-246.91 %)	2022 Q2
-0.17	-0.59 (-240.25 %)	2021 Q4
-0.13	-0.26 (-96.08 %)	2021 Q2
-0.02	-0.32 (-1,444.12 %)	2020 Q4
-0.18	-0.3 (-61.76 %)	2019 Q4

%-지분	이름	주식	변경
13.02793 %	Qiming Venture Partners	57,048,980	0
7.69690 %	Zi (Zhenjun)	33,704,512	-312,537
7.68482 %	Zeng (Min)	33,651,618	0
5.64373 %	DCP Capital	24,713,752	0
1.64022 %	ZhongGeng Fund Management Co., Ltd.	7,182,500	0
1.59351 %	Zhejiang Dinova Ruiying Venture Investment L.P.	6,977,955	0
1.42785 %	Bosera Asset Management Co., Ltd.	6,252,500	0
0.41174 %	SEB Investment Management AB	1,802,986	1,065,545
0.35225 %	Dimensional Fund Advisors, L.P.	1,542,500	-110,000
0.30457 %	E Fund Management Co. Ltd.	1,333,723	0
0.17704 %	Huashang Fund Management Co., Ltd.	775,268	0
0.12640 %	Gu (John Junhua)	553,500	553,500
0.11647 %	California Public Employees' Retirement System	510,000	-25,500
0.10014 %	China Universal Asset Management Co., Ltd.	438,500	0
0.08479 %	Norges Bank Investment Management (NBIM)	371,289	-371,438
0.08187 %	Shanxi Trust Co., Ltd	358,500	0
0.08115 %	Guotai Asset Management Co., Ltd.	355,357	0
0.04017 %	Bellevue Asset Management AG	175,885	0
0.03779 %	Dimensional Fund Advisors, Ltd.	165,500	0
0.03574 %	Nuveen LLC	156,500	0
0.02424 %	Geode Capital Management, L.L.C.	106,144	837
0.01404 %	Harvest Fund Management Co., Ltd.	61,500	0
0.01325 %	State Street Global Advisors Ireland Limited	58,000	0
0.01062 %	American Century Investment Management, Inc.	46,500	-500
0.00959 %	Guliver Anlageberatung GmbH	42,000	0
0.00956 %	FIL Investment Management (Hong Kong) Limited	41,869	-63,858
0.00845 %	Ma (Liqiao)	37,000	37,000
0.00103 %	Storebrand Kapitalforvaltning AS	4,500	0
0.00092 %	Wellington Management Company, LLP	4,019	0
0.00083 %	FIL Investment Management (Australia) Limited	3,618	40
0.00034 %	Avantis Investors_NLE	1,500	500
0.00000 %	China Merchants Fund Management Co. Ltd.	5	0
0 %	China Asset Management (Hong Kong) Limited	0	-116,000
0 %	Fidelity Investments Canada ULC	0	-653,836
0 %	Fidelity Management & Research (Hong Kong) Limited	0	-3,565,459
0 %	Wellington Management Singapore Pte. Ltd.	0	-1,132,000
0 %	Essence Fund Management Co., Ltd.	0	-49,500
0 %	DWS Investments UK Limited	0	-2,687
0 %	Mirae Asset Global Investments (USA) LLC	0	-102,940
0 %	Greiff capital management AG	0	-42,000
0 %	CCB Principal Asset Management Co., Ltd.	0	-27,000
0 %	China Southern Asset Management Co. Ltd.	0	-76,000
0 %	Vanguard Investments Australia Ltd.	0	-25,973
0 %	British Columbia Investment Management Corp.	0	-1,192,895
0 %	Amundi Ireland Limited	0	-22,000
0 %	Boston Partners	0	-6,000
0 %	State Street Global Advisors (UK) Ltd.	0	-58,000
0 %	Amundi (UK)	0	-395,000
0 %	The Vanguard Group, Inc.	0	-9,004,877
0 %	Amundi Japan Ltd.	0	-12,000
0 %	HSBC Global Asset Management (UK) Limited	0	-35,229
0 %	JPMorgan Asset Management U.K. Limited	0	-890,000
0 %	BlackRock Advisors (UK) Limited	0	-1,477,000
0 %	Fidelity International	0	-484,500
0 %	BlackRock Institutional Trust Company, N.A.	0	-3,501,500
0 %	State Street Global Advisors (US)	0	-63,500
0 %	1832 Asset Management L.P.	0	-1,045,600
0 %	Vanguard Global Advisers LLC	0	-24,500

What values and corporate philosophy does Venus Medtech Hangzhou represent?

Venus Medtech Hangzhou Inc represents a strong set of values and corporate philosophy. With a focus on innovation and patient-centered care, the company strives to provide cutting-edge medical solutions. Venus Medtech Hangzhou Inc prioritizes quality, integrity, and transparency in all aspects of its business operations. With a passionate commitment to improving patient outcomes, the company nurtures a culture of excellence and collaboration. Venus Medtech Hangzhou Inc continuously advances its research and development efforts to create revolutionary cardiovascular technologies. As a result, the company has gained recognition for its dedication to harnessing the power of science and technology to enhance healthcare globally.

In which countries and regions is Venus Medtech Hangzhou primarily present?

Venus Medtech Hangzhou Inc is primarily present in China, where it is headquartered in Hangzhou City, Zhejiang Province. As a leading medical technology company, Venus Medtech has established a strong presence in various Chinese provinces and regions, including Beijing, Shanghai, Guangdong, and Jiangsu. With its innovative cardiac valve products and advanced medical solutions, Venus Medtech is also expanding its footprint globally. The company has successfully expanded into international markets such as Europe, especially in Germany, France, Italy, and the United Kingdom. Venus Medtech Hangzhou Inc continues to strive for further global expansion and enhancing patient care worldwide.

What significant milestones has the company Venus Medtech Hangzhou achieved?

Venus Medtech Hangzhou Inc has achieved several significant milestones. The company successfully developed and commercialized the Venus A-valve, a transcatheter aortic valve implantation (TAVI) system. This innovative product has revolutionized the treatment of aortic valve diseases, providing a less invasive option for patients. Venus Medtech also obtained the CE mark and the Chinese FDA approval for the Venus A-valve, expanding its market reach. The company's dedication to research and development led to the successful completion of clinical trials and collaborations with renowned medical institutions worldwide. With these achievements, Venus Medtech Hangzhou Inc has positioned itself as a global leader in cardiovascular medical devices.

What is the history and background of the company Venus Medtech Hangzhou?

Venus Medtech Hangzhou Inc is a leading medical device company specializing in innovative heart valve technologies. Established in Hangzhou, China, the company has a rich history of continuous improvement and breakthroughs in the field of cardiovascular health. Founded in [year], Venus Medtech has become a prominent player in the global medical device industry, providing life-saving solutions for patients with heart valve diseases. They are renowned for their expertise in transcatheter aortic valve replacement (TAVR) therapies, offering cutting-edge products that ensure improved clinical outcomes. With a strong commitment to research and development, Venus Medtech Hangzhou Inc has emerged as a trusted name in the global healthcare sector, revolutionizing the treatment of heart diseases.

Who are the main competitors of Venus Medtech Hangzhou in the market?

The main competitors of Venus Medtech Hangzhou Inc in the market are company A, company B, and company C.

In which industries is Venus Medtech Hangzhou primarily active?

Venus Medtech Hangzhou Inc is primarily active in the medical equipment industry. They specialize in developing and manufacturing innovative heart valve products, aiming to provide better treatment options for patients suffering from heart valve diseases. With their advanced technology and expertise in the field, Venus Medtech is committed to improving the quality of life for individuals in need of heart valve therapies. Their dedication to this industry has made them a leading company in the medical equipment market, continuously pushing boundaries and driving advancements in heart valve treatment solutions.

What is the business model of Venus Medtech Hangzhou?

Venus Medtech Hangzhou Inc operates under the business model of developing and commercializing medical devices for the treatment of structural heart diseases. Their focus is on the design, production, and distribution of transcatheter heart valve replacement systems. Venus Medtech strives to provide innovative and high-quality solutions that improve patient outcomes and enhance the quality of life for individuals with cardiovascular conditions. Through their commitment to research and development, clinical trials, and strategic partnerships, Venus Medtech aims to revolutionize the treatment options available for structural heart diseases.

Venus Medtech Hangzhou 2025의 P/E 비율은 얼마입니까?

Venus Medtech Hangzhou의 P/E 비율은 -6.51입니다.

Venus Medtech Hangzhou 2025의 KUV는 얼마입니까?

Venus Medtech Hangzhou의 P/S 비율은 2.56입니다.

Venus Medtech Hangzhou의 AlleAktien 품질 점수는 얼마인가요?

Venus Medtech Hangzhou에 대한 AlleAktien 품질 점수는 3/10입니다.

Venus Medtech Hangzhou 2025의 매출은 얼마인가요?

예상되는 Venus Medtech Hangzhou 매출은 738.47 백만 CNY입니다.

Venus Medtech Hangzhou 2025의 이익은 얼마인가요?

예상되는 Venus Medtech Hangzhou 이익은 -290.33 백만 CNY입니다.

Venus Medtech Hangzhou은 무엇을 하나요?

Venus Medtech Hangzhou Inc is a Chinese medical technology company that specializes in the development, manufacturing, and marketing of minimally invasive devices and products for cardiovascular diagnostics and intervention. The company offers a wide range of products, including coronary stents, peripheral stents, embolization materials, and transcatheter heart valves. Venus Medtech is a leading provider of coronary stents in China and has a growing presence internationally. The company has developed patented technologies to ensure improved performance and safety of their stents. They have also leveraged their expertise in minimally invasive procedures to develop a range of products for transkatheter heart valves. Additionally, Venus Medtech offers embolization therapy products for blocking blood vessels in various medical conditions. They work closely with leading clinics and specialists in the field of minimally invasive procedures and are dedicated to providing innovative technologies and products to meet the needs of their customers and patients. The company also provides training programs for medical professionals and has an active research and development department focused on advancing minimally invasive medicine. In summary, Venus Medtech Hangzhou Inc is a leading provider of minimally invasive devices and products for cardiovascular diagnostics and intervention, with a wide product range, patented technologies, and a dedicated research and development team.

Venus Medtech Hangzhou 배당금은 얼마입니까?

Venus Medtech Hangzhou은(는) 연간 번의 배당을 통해 0 CNY의 배당금을 지급합니다.

Venus Medtech Hangzhou이 얼마나 자주 배당을 지급하나요?

Venus Medtech Hangzhou의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Venus Medtech Hangzhou ISIN이 무엇입니까?

Venus Medtech Hangzhou의 ISIN은 CNE100003PJ8입니다.

Venus Medtech Hangzhou 티커는 무엇인가요?

Venus Medtech Hangzhou의 티커는 2500.HK입니다.

Venus Medtech Hangzhou이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Venus Medtech Hangzhou은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Venus Medtech Hangzhou은(는) 0 CNY의 배당금을 지급할 것으로 예상됩니다.

Venus Medtech Hangzhou의 배당 수익률은 얼마입니까?

Venus Medtech Hangzhou의 현재 배당 수익률은 입니다.

Venus Medtech Hangzhou의 배당금은 언제 지급되나요?

Venus Medtech Hangzhou은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Venus Medtech Hangzhou의 배당금은 얼마나 안전한가요?

Venus Medtech Hangzhou은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Venus Medtech Hangzhou의 배당금은 얼마입니까?

향후 12개월 동안 0 CNY의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Venus Medtech Hangzhou이(가) 속해 있는 섹터는 어디인가요?

Venus Medtech Hangzhou은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Venus Medtech Hangzhou kaufen, um die vorherige Dividende zu erhalten?

Venus Medtech Hangzhou의 마지막 배당금을 0 CNY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Venus Medtech Hangzhou의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Venus Medtech Hangzhou의 2024년도 배당금은 얼마였습니까?

2024년에 Venus Medtech Hangzhou는 0 CNY를 배당금으로 지급했습니다.

Venus Medtech Hangzhou는 어떤 화폐로 배당금을 지급하나요?

Venus Medtech Hangzhou의 배당금은 CNY에 지급됩니다.

Scope 1 - 직접 방출	88.82
스코프 2 - 구매한 에너지로부터의 간접적인 배출	4,020.62
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량	4,109.43
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율	56.9
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

Venus Medtech Hangzhou 티커	Venus Medtech Hangzhou FIGI
2500:HK	BBG00QTMSFW3
2500:H2	BBG00YPQV4R8
VMTHF:US	BBG00Z1W7X37
VMTHF:PQ	BBG00Z1W7XJ0
VMTHF:UV	BBG00Z1W7XK8
2500:H1	BBG012DZLK04

한눈에 저평가된 주식을 인식하세요

Venus Medtech Hangzhou 주식 2500.HK

가격

가격

티커2500.HK

ISINCNE100003PJ8

Venus Medtech Hangzhou 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Venus Medtech Hangzhou 주가 이력

Venus Medtech Hangzhou 주식 매출, EBIT, 이익

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Venus Medtech Hangzhou 매출, 이익 및 EBIT 역사

Venus Medtech Hangzhou 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Venus Medtech Hangzhou 주식 마진

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Venus Medtech Hangzhou 마진 역사

Venus Medtech Hangzhou 주식 매출, EBIT, 주당 순이익

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Venus Medtech Hangzhou 매출, 이익 및 EBIT 주당 역사

Venus Medtech Hangzhou 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

Venus Medtech Hangzhou Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Venus Medtech Hangzhou 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

Venus Medtech Hangzhou 주식 수량

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

Venus Medtech Hangzhou 수익 예상

Venus Medtech Hangzhou 수익 놀라움

Eulerpool ESG Scorecard© Venus Medtech Hangzhou 주식을 위해

Eulerpool World ESG Rating (EESG©)

83/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

티커
2500.HK

ISIN
CNE100003PJ8